Biogen (BIIB) Tops Q3 EPS by 66c, Updates FY Guidance

Biogen (NASDAQ: BIIB) reported Q3 EPS of $4.77, $0.66 better than the analyst estimate of $4.11. Revenue for the quarter came in at $2.78 million versus the consensus estimate of $2.67 million.

GUIDANCE:

Biogen sees FY2021 EPS of $18.85-$19.35, versus the consensus of $18.61. Biogen sees FY2021 revenue of $10.8-10.9 billion, versus the consensus of $10.76 billion.

For earnings history and earnings-related data on Biogen (BIIB) click here.

You May Also Be Interested In

• Stran & Company, Inc. (SWAG) Reports Q2 EPS of $0.02
• Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
• Adecoagro S.A. (AGRO) Misses Q2 EPS by 63c